Novartis AG
CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) AND CD22 CAR COMBINATION THERAPIES
Last updated:
Abstract:
The invention provides compositions and methods for treating cancer, e.g., hematological cancer, by administering a CD19 CAR-expressing cell as described herein, in combination with a CD22 CAR-expressing cell as described herein.
Status:
Application
Type:
Utility
Filling date:
27 Sep 2019
Issue date:
11 Nov 2021